149 related articles for article (PubMed ID: 26261254)
1. Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma.
Gleeson M; Hawkes EA; Cunningham D; Jack A; Linch D
J Clin Oncol; 2015 Oct; 33(28):3215-6. PubMed ID: 26261254
[No Abstract] [Full Text] [Related]
2. Reply to M. Gleeson et al.
Nowakowski GS; Macon WR; Gascoyne RD; Witzig TE
J Clin Oncol; 2015 Oct; 33(28):3216-7. PubMed ID: 26261258
[No Abstract] [Full Text] [Related]
3. Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care.
Dada R
Acta Haematol; 2017; 138(4):216-220. PubMed ID: 29212067
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
6. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Fowler NH
Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
[No Abstract] [Full Text] [Related]
7. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Zinzani PL; Pellegrini C; Argnani L; Broccoli A
Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
[No Abstract] [Full Text] [Related]
8. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Reddy NM; Greer JP; Morgan DS; Chen H; Park SI; Richards KL
Leukemia; 2017 Jan; 31(1):241-244. PubMed ID: 27654851
[No Abstract] [Full Text] [Related]
10. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
Desai M; Newberry KJ; Romaguera J; Zhang L; Ou Z; Wang M
J Hematol Oncol; 2013 Aug; 6():55. PubMed ID: 23915913
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide for the treatment of B-cell lymphoma.
Garciaz S; Coso D; Schiano de Colella JM; Bouabdallah R
Expert Opin Investig Drugs; 2016 Sep; 25(9):1103-16. PubMed ID: 27414850
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of diffuse large B-cell lymphoma].
Gleissner B; Zwick C; Pfreundschuh M
Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
Zinzani PL; Pellegrini C; Derenzini E; Argnani L; Pileri S
Hematol Oncol; 2013 Dec; 31(4):223-4. PubMed ID: 23620452
[No Abstract] [Full Text] [Related]
15. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
16. [Standard of care and new drugs for diffuse large B-cell lymphoma].
Yamamoto K
Rinsho Ketsueki; 2014 Oct; 55(10):1920-8. PubMed ID: 25297756
[No Abstract] [Full Text] [Related]
17. Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.
Marangon M; Stefoni V; Castellino A; Visco C; Tani M; Cox MC; Marasca R; Tecchio C; Devizzi L; Monaco F; Romano A; Rusconi C; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e321-e323. PubMed ID: 31080169
[No Abstract] [Full Text] [Related]
18. Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment.
Ma LY; Su L
Chin Med J (Engl); 2018 Oct; 131(20):2510-2513. PubMed ID: 30334543
[No Abstract] [Full Text] [Related]
19. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
20. Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
Krawczyk K; Jurczak W; Gałązka K; Gruchała A; Skotnicki AB
J Med Case Rep; 2014 Oct; 8():325. PubMed ID: 25277681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
